Skip to content
Bored Studies
RecruitingPhase 2

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Regeneron Pharmaceuticals · NCT07685808

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
360
US sites recruiting
21
Study start
July 28, 2026
Record last updated
October 26, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes.

The study is looking at

  • What side effects the study drug might cause
  • How much study drug is in the blood at different times
  • How well the study drug works
  • What effects the study drug may have on the body at different dosing schedules
  • If the body makes antibodies to the study drug as this may cause the study drug to not work as well

Being studied: Olatorepatide; Placebo

Conditions: Overweight or Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Body Mass Index (BMI) ≥30.0 kg/m\^2 to \<45.0 kg/m\^2 at screening OR
  • BMI ≥27.0 kg/m\^2 at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary Artery Disease (CAD), Heart failure, established cerebrovascular disease as described in the protocol

Key Exclusion Criteria

  • Previous or current diagnosis of Type 1 or Type 2 diabetes at screening
  • Change in body weight >5 kg within approximately 3 months before screening as described in the protocol
  • Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions as described in the protocol
  • History of acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones
  • History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Recruiting US locations

Study contacts (from the official record)

  • Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
All weight loss studies in Alabama →
Study of Olatorepatide in Adult Participants Living With… (NCT07685808) | Bored Studies